Data gathered: October 5
Alternative Data for enGenes
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Google Trends | 11 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 906 | Sign up | Sign up | Sign up |
| Twitter Mentions | 66 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About enGenes
enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The company is headquartered in Saint-Laurent, Canada.
| Price | $6.63 |
| Target Price | Sign up |
| Volume | 106,840 |
| Market Cap | $293M |
| Year Range | $5.26 - $18.24 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Insider Buying: CEO Cooper Ronald Harold Wilfred Acquires Shares of enGene Holdings Inc (ENGN)September 30 - GuruFocus |
|
 |
Insider Buys Additional US$57k In enGene Holdings StockOctober 2 - Yahoo |
 |
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)October 1 - Yahoo |
Buy Rating Affirmed on enGene Holdings Amidst Promising Efficacy Data and Strategic Protocol AmendmentsSeptember 28 - TipRanks |
|
Buy Rating Affirmed for enGene Holdings Amid Promising Phase 2 Results and Strategic Clinical ExpansionSeptember 28 - TipRanks |
|
EnGene Holdings Inc. - Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal CohortSeptember 26 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 5.2M | -5.2M | -14M | 17M | -0.320 |
| Q2 '24 | 0 | 7.5M | -8.2M | -15M | -14M | -0.380 |
| Q1 '24 | 0 | 5.1M | -6.1M | -11M | -9.7M | -0.462 |
| Q4 '23 | 0 | 0 | 0 | -82M | -63M | -4.512 |
| Q3 '23 | 0 | 0 | 0 | -4.7M | -8.8M | -0.003 |
Insider Transactions View All
| Cooper Ronald Harold Wilfred filed to buy 10,000 shares at $5.7. October 1 '24 |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC filed to sell 3,036,153 shares at $15. April 22 '24 |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC filed to sell 3,084,007 shares at $15. April 22 '24 |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC filed to sell 3,084,107 shares at $15. April 22 '24 |
Similar companies
Read more about enGenes (ENGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of enGenes?
The Market Cap of enGenes is $293M.
What is the current stock price of enGenes?
Currently, the price of one share of enGenes stock is $6.63.
How can I analyze the ENGN stock price chart for investment decisions?
The ENGN stock price chart above provides a comprehensive visual representation of enGenes' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling enGenes shares. Our platform offers an up-to-date ENGN stock price chart, along with technical data analysis and alternative data insights.
Does ENGN offer dividends to its shareholders?
As of our latest update, enGenes (ENGN) does not offer dividends to its shareholders. Investors interested in enGenes should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of enGenes?
Some of the similar stocks of enGenes are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.